Published in Oncologist on August 21, 2013
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol (2008) 10.91
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res (2008) 10.66
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol (2012) 6.49
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol (2004) 4.25
Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem (1995) 3.72
Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol (1994) 3.19
The 16,17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3beta-ol) and related steroidal inhibitors. J Med Chem (1998) 2.08
Effects of novel 17alpha-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo. J Steroid Biochem Mol Biol (2003) 1.23
In vitro and in vivo models for the evaluation of potent inhibitors of male rat 17alpha-hydroxylase/C17,20-lyase. J Steroid Biochem Mol Biol (2003) 0.85
Novel steroidal pyrimidyl inhibitors of P450 17 (17 alpha-hydroxylase/C17-20-lyase). Arch Pharm (Weinheim) (2001) 0.79
Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma. Nat Rev Drug Discov (2008) 3.35
Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med (2015) 3.09
Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol (2002) 2.10
New drug approval success rate in Europe in 2009. Nat Rev Drug Discov (2010) 1.97
Safe drugs and the cost of good intentions. N Engl J Med (2009) 1.84
Access to patient-level trial data--a boon to drug developers. N Engl J Med (2013) 1.72
Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol (2005) 1.66
Near-field interference for the unidirectional excitation of electromagnetic guided modes. Science (2013) 1.61
The risks of risk aversion in drug regulation. Nat Rev Drug Discov (2013) 1.55
The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. Breast Cancer Res Treat (2010) 1.50
Effect of radiation, heat, and aging on in vitro wear resistance of polyethylene. Clin Orthop Relat Res (2003) 1.39
A guide for reporting the results of population pharmacokinetic analyses: a Swedish perspective. AAPS J (2005) 1.24
A regulatory Apologia--a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur Neuropsychopharmacol (2008) 1.19
Data storage: The third plasmonic revolution. Nat Nanotechnol (2010) 1.07
Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial. Clin Cancer Res (2013) 1.03
Role of modelling and simulation: a European regulatory perspective. Clin Pharmacokinet (2012) 1.01
Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH. Diagn Mol Pathol (2009) 0.97
Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother Pharmacol (2002) 0.95
The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use. Clin Cancer Res (2012) 0.95
Regulatory evaluation of Glybera in Europe - two committees, one mission. Nat Rev Drug Discov (2013) 0.94
Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency. Trials (2014) 0.93
Loss of GSTM1, a NRF2 target, is associated with accelerated progression of hypertensive kidney disease in the African American Study of Kidney Disease (AASK). Am J Physiol Renal Physiol (2012) 0.92
Effects of titanium particle size on osteoblast functions in vitro and in vivo. Proc Natl Acad Sci U S A (2005) 0.91
Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE). Neuroendocrinology (2013) 0.88
Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002. Int J Clin Oncol (2002) 0.88
Reimaging in pediatric neurotrauma: factors associated with progression of intracranial injury. J Pediatr Surg (2002) 0.87
Spinophilin loss correlates with poor patient prognosis in advanced stages of colon carcinoma. Clin Cancer Res (2013) 0.86
A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors. Oncologist (2002) 0.85
MDCT and MRI evaluation of cervical spine trauma. Insights Imaging (2013) 0.84
A survey of Australian and New Zealand old age psychiatrists' preferred medications to treat behavioral and psychological symptoms of dementia (BPSD). Int Psychogeriatr (2005) 0.84
Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer. Anticancer Res (2003) 0.84
A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies. Invest New Drugs (2004) 0.82
New targeted agents in gastroenteropancreatic neuroendocrine tumors. Target Oncol (2012) 0.82
Seroprevalence and placental transmission of maternal antibodies specific for Neisseria meningitidis Serogroups A, C, Y and W135 and influence of maternal antibodies on the immune response to a primary course of MenACWY-CRM vaccine in the United Kingdom. Pediatr Infect Dis J (2013) 0.82
The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Clin Cancer Res (2011) 0.82
Automated, Depth-Resolved Estimation of the Attenuation Coefficient From Optical Coherence Tomography Data. IEEE Trans Med Imaging (2015) 0.81
PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome. BMC Cancer (2012) 0.81
The B-cell response to a primary and booster course of MenACWY-CRM₁₉₇ vaccine administered at 2, 4 and 12 months of age. Vaccine (2013) 0.81
International price comparisons of Alzheimer's drugs: a way to close the affordability gap. Int Psychogeriatr (2009) 0.81
Single nucleotide polymorphisms in the Toll-like receptor 3 and CD44 genes are associated with persistence of vaccine-induced immunity to the serogroup C meningococcal conjugate vaccine. Clin Vaccine Immunol (2011) 0.81
Immunohistochemical assessment of Pax8 expression during pancreatic islet development and in human neuroendocrine tumors. Histochem Cell Biol (2011) 0.79
Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial. Cancer Chemother Pharmacol (2014) 0.78
Care planning practices for behavioural and psychological symptoms of dementia in residential aged care: a pilot of an education toolkit informed by the Aged Care Funding Instrument. Contemp Nurse (2013) 0.77
An audit of physical restraint and seclusion in five psychogeriatric admission wards in Victoria, Australia. Int J Geriatr Psychiatry (2004) 0.77
Regulatory aspects of pharmacokinetic profiling in special populations: a European perspective. Clin Pharmacokinet (2008) 0.77
Individualized guidelines for the management of aggression in dementia - Part 1: key concepts. Int Psychogeriatr (2012) 0.77
Linaclotide for treatment of irritable bowel syndrome--the view of European regulators. Dig Liver Dis (2013) 0.76
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents. Neuroendocrinology (2017) 0.75
An open-label, dose-finding study of the combination of satraplatin and gemcitabine in patients with advanced solid tumors. Front Oncol (2012) 0.75
Is it time to abandon complete blinded independent central radiological evaluation of progression in registration trials? Eur J Cancer (2011) 0.75
[The Medical Product Agency's work and economics--a comment]. Lakartidningen (2003) 0.75
[Generic preparations are equivalent]. Lakartidningen (2008) 0.75
EMEA and Gene Therapy Medicinal Products Development in the European Union. J Biomed Biotechnol (2003) 0.75
Pax8 detection in well-differentiated pancreatic endocrine tumors: how reliable is it? Am J Surg Pathol (2011) 0.75
Use of biomarkers in the context of orphan medicines designation in the European Union. Orphanet J Rare Dis (2014) 0.75
Tissue compression is not necessary for needle-localized lesion identification. Am J Surg (2005) 0.75
Quadrature wavelength scanning interferometry. Appl Opt (2016) 0.75
How well do Australian medical schools prepare general practitioners to care for patients with mental disorders? Australas Psychiatry (2004) 0.75
Evaluation Of Energy Intake At A Range Of Energy Flux Derived From Self-report, Doubly Labeled Water, And Activity Monitors: 1979 Board #131 June 2, 2: 00 PM - 3: 30 PM. Med Sci Sports Exerc (2016) 0.75
Where is industry getting it wrong? A review of quality concerns raised at Day 120 by the Committee For Medicinal Products for Human Use during European Centralised Marketing Authorisation Submissions for Chemical Entity Medicinal Products. J Pharm Pharm Sci (2009) 0.75
A truncated mouse phenylethanolamine N-methyltransferase splice variant with dominant-negative activity. Ann N Y Acad Sci (2002) 0.75
Genetic material should be routinely collected in clinical vaccine trials--high consent rates can be achieved across all age groups. Vaccine (2013) 0.75
Phase and fringe order determination in wavelength scanning interferometry. Opt Express (2016) 0.75
Individualized guidelines for the management of aggression in dementia - Part 2: appraisal of current guidelines. Int Psychogeriatr (2012) 0.75
The European Medicines Agency approval of 5-aminolaevulinic acid (Ameluz) for the treatment of actinic keratosis of mild to moderate intensity on the face and scalp: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. J Dermatolog Treat (2013) 0.75
Model-based defect detection on structured surfaces having optically unresolved features. Appl Opt (2015) 0.75
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors. Neuroendocrinology (2017) 0.75
Correction: Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src. Oncotarget (2016) 0.75
Retrospective comparison of freehand and ultrasound-guided shoulder steroid injections. Orthopedics (2011) 0.75
A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors. Cancer (2003) 0.75